Angirid MR 35 mg Tab

Angirid MR 35 mg Tab

DESCRIPTION

ANGIRID MR (Trimetazidine Hydrochloride) has been proven to exert antianginal properties due to its specific metabolic mechanism of action. Indeed, Trimetazidine Hydrochloride reduces the metabolic damage caused during ischemia, by acting on a critical step in cardiac metabolism: fatty acid β-oxidation. This is made possible by selective inhibition of an enzyme of fatty acid βoxidation: the long-chain 3-ketoacyl CoA thiolase (3-KAT). This inhibition results in reduction in fatty acid oxidation & stimulation of glucose oxidation. Thus, the coupling of glycolysis with glucose oxidation is improved, and ATP production is further increased, while the deleterious consequences of acidosis and of Ca2+ overload are limited.

COMPOSITION

ANGIRID MR : Each modified release tablet contains Trimetazidine Hydrochloride BP 35 mg.

INDICATIONS

Long-term treatment of angina pectoris.

DOSAGE & ADMINISTRATION

1 tablet at mealtimes in the morning and evening.

SIDE EFFECTS

Rare cases of gastrointestinal disorders.

CONTRAINDICATIONS

Trimetazidine is contraindicated in-patients with a known hypersensitivity to its components.

USE IN PREGNANCY AND LACTATION

Pregnancy : Studies in animals have not demonstrated ateratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy. Breastfeeding : In the absence of data, breastfeeding is not recommended during treatment.

DRUG INTERACTIONS

No Drug Interactions so far have been reported. In particular, no interactions have been reported with beta-blocker, calcium antagonists, nitrates, heparin, hypolipidaemic agents or digitals preparation.

SUPPLY

Each box contains 3 x 10 tablets in blister strips